Active surveillance up in multidisciplinary prostate CA care

August 1, 2012
Active surveillance up in multidisciplinary prostate CA care
Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, according to a study published online July 30 in the Journal of Clinical Oncology.

(HealthDay) -- Men with low-risk prostate cancer are more likely to pursue active surveillance when seen at a multidisciplinary prostate cancer clinic rather than when they see individual specialists in sequential settings, according to a study published online July 30 in the Journal of Clinical Oncology.

To examine the factors associated with active surveillance in patients with low-risk prostate cancer, Ayal A. Aizer, M.D., M.H.S., of Massachusetts General Hospital in Boston, and colleagues conducted a study involving 701 men who were either treated at a multidisciplinary prostate cancer clinic with a team consisting of an urologist and radiation and medical oncologists, or who saw individual specialists sequentially.

The researchers found the crude rates of active surveillance to be almost double for those seen in the multidisciplinary clinic compared with those seen by individual physicians (43 versus 22 percent), while the proportion treated with or was reduced by about 30 percent. The pursuit of active surveillance was significantly associated with consultation at a multidisciplinary clinic (odds ratio [OR], 2.15), older age (OR, 1.09), unmarried status (OR, 1.66), increased Charlson comorbidity index (OR, 1.37), and fewer positive cores (OR, 0.92).

"In conclusion, our study indicates that multidisciplinary care is associated with a significantly increased rate of active surveillance in men with low-risk , a finding that may have an important clinical, social, and economic impact," the authors write.

Explore further: Active surveillance cost-effective for prostate cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Active surveillance cost-effective for prostate cancer

July 13, 2012
(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, according ...

New approach to prostate cancer care draws patients with riskiest disease

January 5, 2012
(Medical Xpress) -- In choosing where they get treatment, prostate cancer patients tend to opt for a major cancer center if they have severe disease, but stick closer to home for less complicated cases, even when offered ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Mutant gene found to fuel cancer-promoting effects of inflammation

October 19, 2017
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

JGE
not rated yet Aug 15, 2012
Now known to most scientific support morbildad caused by the procedures to diagnose and treat prostate cancer, active surveillance is a well indicated for selected patients. We need a report or report of consensus which categorically its indication and scope

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.